Arbutus Biopharma Files 8-K, Changes Address
Ticker: ABUS · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: administrative, address-change
Related Tickers: ABUS
TL;DR
Arbutus Biopharma (ABUS) moved its HQ to PA, formerly Tekmira.
AI Summary
Arbutus Biopharma Corporation filed an 8-K on June 6, 2024, to report other events and financial statements. The filing indicates a change in the company's principal executive offices to 701 Veterans Circle, Warminster, Pennsylvania, 18974. The company was formerly known as Tekmira Pharmaceuticals Corp.
Why It Matters
This filing updates the company's principal executive office location, which is important for official correspondence and regulatory purposes.
Risk Assessment
Risk Level: low — This is a routine administrative filing regarding a change of address and historical company name information.
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- 701 Veterans Circle, Warminster, Pennsylvania, 18974 (location) — New Principal Executive Offices
- June 6, 2024 (date) — Date of Report
FAQ
What is the new principal executive office address for Arbutus Biopharma Corporation?
The new principal executive office address is 701 Veterans Circle, Warminster, Pennsylvania, 18974.
When was the report filed?
The report was filed on June 6, 2024.
What was Arbutus Biopharma Corporation's former name?
Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.
What is the company's state of incorporation?
The company is incorporated in British Columbia, Canada.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 98-0597776.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-06 11:16:15
Filing Documents
- f8k_060524.htm (8-K) — 16KB
- exh_991.htm (EX-99.1) — 13KB
- exh_992.htm (EX-99.2) — 40KB
- exh992_01.jpg (GRAPHIC) — 108KB
- exh992_02.jpg (GRAPHIC) — 239KB
- exh992_03.jpg (GRAPHIC) — 98KB
- exh992_04.jpg (GRAPHIC) — 158KB
- exh992_05.jpg (GRAPHIC) — 82KB
- exh992_06.jpg (GRAPHIC) — 115KB
- exh992_07.jpg (GRAPHIC) — 161KB
- exh992_08.jpg (GRAPHIC) — 110KB
- exh992_09.jpg (GRAPHIC) — 128KB
- exh992_10.jpg (GRAPHIC) — 109KB
- exh992_11.jpg (GRAPHIC) — 134KB
- exh992_12.jpg (GRAPHIC) — 162KB
- exh992_13.jpg (GRAPHIC) — 203KB
- exh992_14.jpg (GRAPHIC) — 203KB
- exh992_15.jpg (GRAPHIC) — 157KB
- exh992_16.jpg (GRAPHIC) — 203KB
- exh992_17.jpg (GRAPHIC) — 178KB
- exh992_18.jpg (GRAPHIC) — 113KB
- exh992_19.jpg (GRAPHIC) — 108KB
- exh992_20.jpg (GRAPHIC) — 129KB
- exh992_21.jpg (GRAPHIC) — 144KB
- exh992_22.jpg (GRAPHIC) — 123KB
- exh992_23.jpg (GRAPHIC) — 169KB
- exh992_24.jpg (GRAPHIC) — 108KB
- exh992_25.jpg (GRAPHIC) — 103KB
- exh992_26.jpg (GRAPHIC) — 93KB
- 0001171843-24-003323.txt ( ) — 5294KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_060524_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On June 6, 2024, Arbutus Biopharma Corporation ("Arbutus" or the "Company") issued a press release announcing new preliminary end-of-treatment (EOT) data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in patients receiving ongoing standard-of-care nucleos(t)ide analogue (NA) therapy indicating that treatment with imdusiran, Arbutus' RNAi therapeutic, followed by Barinthus Biotherapeutic's T-cell stimulating immunotherapeutic, VTP-300, was generally safe, well-tolerated and led to maintenance of lower HBsAg levels during the post-treatment follow-up period in patients with cHBV. The data were presented today by Dr. Kosh Agarwal, MD, Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies at King's College Hospital, London, during a session focused on new treatments for viral hepatitis B at the European Association for the Study of the Liver (EASL) Congress. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. On June 6, 2024, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated June 6, 2024 99.2 Presentation dated June 6, 2024 104 Cover page interactive data file (formatted as inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: June 6, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer